Positions

Selected Publications

Academic Article

Year Title Altmetric
2021 Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma..  Journal of Clinical Oncology.  JCO2101935. 2021
2021 Impact of t(11;14) as a sole and concomitant abnormality on outcomes in multiple myeloma.  British Journal of Haematology.  195:e113-e116. 2021
2021 Phase II clinical trial of one dose of post-transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matched-unrelated donor transplantation.  American Journal of Hematology.  96:E396-E398. 2021
2021 Autologous stem cell transplantation in the age of ANDROMEDA.  British Journal of Haematology.  193:865-866. 2021
2021 Impact of access to care on 1-year mortality following allogeneic blood or marrow transplantation.  Bone Marrow Transplantation.  56:1364-1372. 2021
2021 Maintaining the minimal: dynamics of measurable residual disease with continuous lenalidomide therapy.  Lancet Haematology.  8:e386-e387. 2021
2021 Caution with Routine Use of Daratumumab for Newly Diagnosed High-Risk Multiple Myeloma - Reply.  JAMA Oncology.  7:635-636. 2021
2021 New regimens and directions in the management of newly diagnosed multiple myeloma.  American Journal of Hematology.  96:367-378. 2021
2021 A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients.  Bone Marrow Transplantation.  2021
2021 International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.  Leukemia.  35:18-30. 2021
2021 Pre-treatment neutrophil to lymphocyte ratio as a biomarker of frailty and predictor of survival among older adults with multiple myeloma.  Journal of Geriatric Oncology.  2021
2021 Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies.  Leukemia.  2021
2020 Age is just a number, the wrong number.  Cancer.  126:5014-5016. 2020
2020 Solid Organ Transplantation 2020
2020 Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma.  Biology of Blood and Marrow Transplantation.  26:1394-1401. 2020
2020 Assessment of measurable residual disease (MRD) in multiple myeloma: a review of the data 2020
2020 Best practices for the assessment of measurable residual disease (MRD) in multiple myeloma 2020
2020 Best practices for the assessment of measurable residual disease (MRD) in multiple myeloma: further observations 2020
2020 Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients with High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis.  JAMA Oncology.  6:1759-1765. 2020
2020 Outcomes of Autologous Hematopoietic Cell Transplantation in Diffuse Large B Cell Lymphoma Refractory to Firstline Chemoimmunotherapy.  Biology of Blood and Marrow Transplantation.  2020
2019 Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma.  British Journal of Haematology.  186:807-819. 2019
2019 Lessons learned from checkpoint blockade targeting PD-1 in multiple myeloma.  Cancer Immunology Research.  7:1224-1229. 2019
2016 The impending financial healthcare burden and ethical dilemma of systemic therapy in metastatic cancer.  Journal of Surgical Oncology.  114:323-328. 2016
2015 Myocardial perfusion imaging determination using an appropriate use smartphone application.  Journal of Nuclear Cardiology.  22:66-71. 2015
2014 Potential of F-18 PET/CT in the Detection of Leptomeningeal Metastasis..  Rivista di Neuroradiologia.  27:685-689. 2014
2011 Long-term outcome of lobar ablation versus completion thyroidectomy in differentiated thyroid cancer.  Nuclear Medicine Communications.  32:52-58. 2011

Principal Investigator On

Investigator On

  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by JUNO THERAPEUTICS
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by CAREVIVE SYSTEMS, INC.
  • Private Grant  awarded by JUNO THERAPEUTICS
  • Private Grant  awarded by JUNO THERAPEUTICS
  • Private Grant  awarded by SUTRO BIOPHARM
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by IONIS PHARMACEUTICALS, INC.
  • Private Grant  awarded by MARKER THERAPEUTICS INC
  • Private Grant  awarded by JUNO THERAPEUTICS
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by FATE THERAPEUTICS, INC.
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by MARKER THERAPEUTICS INC
  • Private Grant  awarded by EUSA PHARMA
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • UAB 1815: Phase 2 Trial of Intensive Chemo-immu,otherapy with Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Relapsed.Refractory Myeloma In the context of Salvage Autologous Hematopoietic Cell Transplantation  awarded by Memorial Sloan-Kettering Cancer Center

    • Education And Training

  • Bachelor of Medicine & Surgery (MBBS), Bharati Vidyapeeth University 2012

    • Full Name

  • Susan Bal